GFM
KYTX icon

GF Fund Management’s Kyverna Therapeutics KYTX Stock Holding History

GF Fund Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.43K Buy
977
+117
+14% +$975 ﹤0.01% 574
2025
Q4 		$8.08K Sell
860
-38
-4% -$282 ﹤0.01% 597
2025
Q3 		$5.39K Sell
898
-172
-16% -$688 ﹤0.01% 606
2025
Q2 		$3.29K Hold
1,070
– – ﹤0.01% 641
2025
Q1 		$2.06K Buy
1,070
+164
+18% +$485 ﹤0.01% 647
2024
Q4 		$3.39K Buy
+906
New +$4.34K ﹤0.01% 625

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

GF Fund Management's KYTX Position: Q1 2026 in Review

GF Fund Management increased its Kyverna Therapeutics (KYTX) stake by 14% in Q1 2026, buying an estimated $975 and bringing the position to 977 shares worth $8.43K. The position accounts for ﹤0.01% of the portfolio, ranked #574.

GF Fund Management first reported a position in KYTX in Q4 2024 and has held it in 6 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • GF Fund Management held 977 shares of Kyverna Therapeutics worth $8.43K as of Q1 2026.
  • GF Fund Management bought 117 Kyverna Therapeutics shares in Q1 2026, an estimated $975.
  • Kyverna Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #574 holding.
  • GF Fund Management first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.